Skip to main content
Erschienen in: Medical Oncology 10/2016

01.10.2016 | Original Paper

Identification of key pathways and genes in colorectal cancer using bioinformatics analysis

verfasst von: Bin Liang, Chunning Li, Jianying Zhao

Erschienen in: Medical Oncology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is the most common malignant tumor of digestive system. The aim of this study was to identify gene signatures during CRC and uncover their potential mechanisms. The gene expression profiles of GSE21815 were downloaded from GEO database. The GSE21815 dataset contained 141 samples, including 132 CRC and 9 normal colon epitheliums. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed, and protein–protein interaction (PPI) network of the differentially expressed genes (DEGs) was constructed by Cytoscape software. In total, 3500 DEGs were identified in CRC, including 1370 up-regulated genes and 2130 down-regulated genes. GO analysis results showed that up-regulated DEGs were significantly enriched in biological processes (BP), including cell cycle, cell division, and cell proliferation; the down-regulated DEGs were significantly enriched in biological processes, including immune response, intracellular signaling cascade and defense response. KEGG pathway analysis showed the up-regulated DEGs were enriched in cell cycle and DNA replication, while the down-regulated DEGs were enriched in drug metabolism, metabolism of xenobiotics by cytochrome P450, and retinol metabolism pathways. The top 10 hub genes, GNG2, AGT, SAA1, ADCY5, LPAR1, NMU, IL8, CXCL12, GNAI1, and CCR2 were identified from the PPI network, and sub-networks revealed these genes were involved in significant pathways, including G protein-coupled receptors signaling pathway, gastrin-CREB signaling pathway via PKC and MAPK, and extracellular matrix organization. In conclusion, the present study indicated that the identified DEGs and hub genes promote our understanding of the molecular mechanisms underlying the development of CRC, and might be used as molecular targets and diagnostic biomarkers for the treatment of CRC.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Zurück zum Zitat Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.CrossRefPubMed Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.CrossRefPubMed
3.
Zurück zum Zitat Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588–99.CrossRefPubMed Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588–99.CrossRefPubMed
4.
Zurück zum Zitat Nannini M, Pantaleo MA, Maleddu A, et al. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009;35:201–9.CrossRefPubMed Nannini M, Pantaleo MA, Maleddu A, et al. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009;35:201–9.CrossRefPubMed
5.
Zurück zum Zitat Bustin SA, Dorudi S. Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Expert Rev Mol Diagn. 2004;4:599–607.CrossRefPubMed Bustin SA, Dorudi S. Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Expert Rev Mol Diagn. 2004;4:599–607.CrossRefPubMed
6.
Zurück zum Zitat Lascorz J, Hemminki K, Forsti A. Systematic enrichment analysis of gene expression profiling studies identifies consensus pathways implicated in colorectal cancer development. J Carcinog. 2011;10:7.CrossRefPubMedPubMedCentral Lascorz J, Hemminki K, Forsti A. Systematic enrichment analysis of gene expression profiling studies identifies consensus pathways implicated in colorectal cancer development. J Carcinog. 2011;10:7.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Iwaya T, Yokobori T, Nishida N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012;33:2391–7.CrossRefPubMed Iwaya T, Yokobori T, Nishida N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012;33:2391–7.CrossRefPubMed
8.
Zurück zum Zitat Gene Ontology C. The gene ontology (GO) project in 2006. Nucleic Acids Res. 2006;34:D322–6.CrossRef Gene Ontology C. The gene ontology (GO) project in 2006. Nucleic Acids Res. 2006;34:D322–6.CrossRef
9.
Zurück zum Zitat Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–9.CrossRefPubMedPubMedCentral Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–9.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.CrossRefPubMed Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.CrossRefPubMed
12.
Zurück zum Zitat Sakai E, Fukuyo M, Ohata K, et al. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int J Cancer. 2016;138:1634–44.CrossRefPubMed Sakai E, Fukuyo M, Ohata K, et al. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int J Cancer. 2016;138:1634–44.CrossRefPubMed
13.
Zurück zum Zitat Gautam V, Singh A, Singh S, Sarkar AK. An efficient LCM-based method for tissue specific expression analysis of genes and miRNAs. Sci Rep. 2016;6:21577.CrossRefPubMedPubMedCentral Gautam V, Singh A, Singh S, Sarkar AK. An efficient LCM-based method for tissue specific expression analysis of genes and miRNAs. Sci Rep. 2016;6:21577.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Mehta P, Premkumar B, Morris R. Production of high quality brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) RNA from isolated populations of rat spinal cord motor neurons obtained by Laser Capture Microdissection (LCM). Neurosci Lett. 2016;627:132–8.CrossRefPubMed Mehta P, Premkumar B, Morris R. Production of high quality brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) RNA from isolated populations of rat spinal cord motor neurons obtained by Laser Capture Microdissection (LCM). Neurosci Lett. 2016;627:132–8.CrossRefPubMed
15.
Zurück zum Zitat Perez R, Wu N, Klipfel AA, Beart RW Jr. A better cell cycle target for gene therapy of colorectal cancer: cyclin G. J Gastrointest Surg. 2003;7:884–9.CrossRefPubMed Perez R, Wu N, Klipfel AA, Beart RW Jr. A better cell cycle target for gene therapy of colorectal cancer: cyclin G. J Gastrointest Surg. 2003;7:884–9.CrossRefPubMed
16.
Zurück zum Zitat Tominaga O, Nita ME, Nagawa H, et al. Expressions of cell cycle regulators in human colorectal cancer cell lines. Jpn J Cancer Res. 1997;88:855–60.CrossRefPubMed Tominaga O, Nita ME, Nagawa H, et al. Expressions of cell cycle regulators in human colorectal cancer cell lines. Jpn J Cancer Res. 1997;88:855–60.CrossRefPubMed
17.
Zurück zum Zitat Tsunoda T, Nakamura T, Ishimoto K, et al. Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. Anticancer Res. 2001;21:137–43.PubMed Tsunoda T, Nakamura T, Ishimoto K, et al. Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. Anticancer Res. 2001;21:137–43.PubMed
18.
Zurück zum Zitat Djamgoz MB, Coombes RC, Schwab A. Ion transport and cancer: from initiation to metastasis. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130092.CrossRefPubMedPubMedCentral Djamgoz MB, Coombes RC, Schwab A. Ion transport and cancer: from initiation to metastasis. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130092.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat An N, Yang X, Zhang Y, et al. Cell cycle related genes up-regulated in human colorectal development predict the overall survival of late-stage colorectal cancer patients. Mol BioSyst. 2016;12:541–52.CrossRefPubMed An N, Yang X, Zhang Y, et al. Cell cycle related genes up-regulated in human colorectal development predict the overall survival of late-stage colorectal cancer patients. Mol BioSyst. 2016;12:541–52.CrossRefPubMed
20.
Zurück zum Zitat Vicente CM, Ricci R, Nader HB, Toma L. Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts. BMC Cell Biol. 2013;14:25.CrossRefPubMedPubMedCentral Vicente CM, Ricci R, Nader HB, Toma L. Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts. BMC Cell Biol. 2013;14:25.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chen D, Yu Z, Zhu Z, Lopez CD. The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res. 2006;66:3485–94.CrossRefPubMed Chen D, Yu Z, Zhu Z, Lopez CD. The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res. 2006;66:3485–94.CrossRefPubMed
22.
Zurück zum Zitat Shen L, Qu X, Ma Y, et al. Tumor suppressor NDRG2 tips the balance of oncogenic TGF-beta via EMT inhibition in colorectal cancer. Oncogenesis. 2014;3:e86.CrossRefPubMedPubMedCentral Shen L, Qu X, Ma Y, et al. Tumor suppressor NDRG2 tips the balance of oncogenic TGF-beta via EMT inhibition in colorectal cancer. Oncogenesis. 2014;3:e86.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Logan CV, Szabadkai G, Sharpe JA, et al. Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. Nat Genet. 2014;46:188–93.CrossRefPubMed Logan CV, Szabadkai G, Sharpe JA, et al. Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. Nat Genet. 2014;46:188–93.CrossRefPubMed
24.
25.
Zurück zum Zitat Yajima I, Kumasaka MY, Yamanoshita O, et al. GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity. Am J Cancer Res. 2014;4:182–8.PubMedPubMedCentral Yajima I, Kumasaka MY, Yamanoshita O, et al. GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity. Am J Cancer Res. 2014;4:182–8.PubMedPubMedCentral
26.
Zurück zum Zitat Citron M, Decker R, Chen S, et al. O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 1991;51:4131–4.PubMed Citron M, Decker R, Chen S, et al. O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 1991;51:4131–4.PubMed
27.
Zurück zum Zitat Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60:2368–71.PubMed Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60:2368–71.PubMed
28.
Zurück zum Zitat Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G: C to A: T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:4689–92.PubMed Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G: C to A: T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:4689–92.PubMed
29.
Zurück zum Zitat Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A. 1994;91:3186–90.CrossRefPubMedPubMedCentral Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A. 1994;91:3186–90.CrossRefPubMedPubMedCentral
30.
32.
Zurück zum Zitat Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol. 2000;279:F400–16.PubMed Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol. 2000;279:F400–16.PubMed
33.
Zurück zum Zitat Jarvandi S, Davidson NO, Schootman M. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. PLoS ONE. 2013;8:e74616.CrossRefPubMedPubMedCentral Jarvandi S, Davidson NO, Schootman M. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. PLoS ONE. 2013;8:e74616.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Wei JS, Johansson P, Chen L, et al. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma. PLoS ONE. 2013;8:e77731.CrossRefPubMedPubMedCentral Wei JS, Johansson P, Chen L, et al. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma. PLoS ONE. 2013;8:e77731.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Wang J, Wang Y, Wang S, et al. Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer. Oncotarget. 2015;6:42825–37.PubMedPubMedCentral Wang J, Wang Y, Wang S, et al. Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer. Oncotarget. 2015;6:42825–37.PubMedPubMedCentral
37.
Zurück zum Zitat Liu F, Yu C. IL-8 promote carcinogenesis of primary epithelial cells from familial adenomatous polyposis. Cell Biochem Biophys. 2014;70:1765–71.CrossRefPubMed Liu F, Yu C. IL-8 promote carcinogenesis of primary epithelial cells from familial adenomatous polyposis. Cell Biochem Biophys. 2014;70:1765–71.CrossRefPubMed
38.
Zurück zum Zitat Sotsios Y, Whittaker GC, Westwick J, Ward SG. The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes. J Immunol. 1999;163:5954–63.PubMed Sotsios Y, Whittaker GC, Westwick J, Ward SG. The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes. J Immunol. 1999;163:5954–63.PubMed
39.
Zurück zum Zitat Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117–30.CrossRefPubMed Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117–30.CrossRefPubMed
40.
Zurück zum Zitat Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697–710.PubMed Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697–710.PubMed
41.
Zurück zum Zitat Zhao L, Lim SY, Gordon-Weeks AN, et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology. 2013;57:829–39.CrossRefPubMed Zhao L, Lim SY, Gordon-Weeks AN, et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology. 2013;57:829–39.CrossRefPubMed
42.
Zurück zum Zitat Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem. 2004;279:3188–96.CrossRefPubMed Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem. 2004;279:3188–96.CrossRefPubMed
43.
Zurück zum Zitat Rieken S, Herroeder S, Sassmann A, et al. Lysophospholipids control integrin-dependent adhesion in splenic B cells through G(i) and G(12)/G(13) family G-proteins but not through G(q)/G(11). J Biol Chem. 2006;281:36985–92.CrossRefPubMed Rieken S, Herroeder S, Sassmann A, et al. Lysophospholipids control integrin-dependent adhesion in splenic B cells through G(i) and G(12)/G(13) family G-proteins but not through G(q)/G(11). J Biol Chem. 2006;281:36985–92.CrossRefPubMed
44.
Zurück zum Zitat Foley JF, Singh SP, Cantu M, et al. Differentiation of human T cells alters their repertoire of G protein alpha-subunits. J Biol Chem. 2010;285:35537–50.CrossRefPubMedPubMedCentral Foley JF, Singh SP, Cantu M, et al. Differentiation of human T cells alters their repertoire of G protein alpha-subunits. J Biol Chem. 2010;285:35537–50.CrossRefPubMedPubMedCentral
46.
47.
Zurück zum Zitat Abramovitch R, Tavor E, Jacob-Hirsch J, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 2004;64:1338–46.CrossRefPubMed Abramovitch R, Tavor E, Jacob-Hirsch J, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 2004;64:1338–46.CrossRefPubMed
Metadaten
Titel
Identification of key pathways and genes in colorectal cancer using bioinformatics analysis
verfasst von
Bin Liang
Chunning Li
Jianying Zhao
Publikationsdatum
01.10.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 10/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0829-6

Weitere Artikel der Ausgabe 10/2016

Medical Oncology 10/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.